沙库巴曲缬沙坦联合螺内酯治疗对射血分数降低型心力衰竭患者心功能指标及运动耐力的影响  

Effects of Sacubitril Valsartan Combined with Spironolactone on Cardiac Function Indicators and Exercise Endurance Patients with Heart Failure with Reduced Ejection Fraction

作　　者：孟凯 程纷纷 MENG Kai;CHENG Fenfen(Department of the Third Cardiology,Jinxing Hospital Affiliated to Jining Medical University,Jinxing 272200,China)

机构地区：[1]济宁医学院附属金乡医院心内三科,山东济宁272200

出　　处：《反射疗法与康复医学》2025年第5期108-111,共4页Reflexology And Rehabilitation Medicine

摘　　要：目的 探讨沙库巴曲缬沙坦联合螺内酯治疗射血分数降低型心力衰竭(HFrEF)患者的临床效果。方法 选取2022年5月—2023年4月济宁医学院附属金乡医院收治的80例HFrEF患者为研究对象,按随机数字表法将其分为对照组(n=40)和观察组(n=40)。对照组采用螺内酯治疗,观察组在对照组基础上采用沙库巴曲缬沙坦治疗,两组均持续治疗2个月。比较两组的临床疗效、心功能指标、运动耐力、不良反应发生情况、不良事件发生情况。结果 观察组治疗总有效率为97.50%,高于对照组的77.50%,差异有统计学意义(P<0.05)。治疗后,观察组左室舒张末期内径、左室收缩末期内径均短于对照组,左心射血分数高于对照组,6 min步行试验距离长于对照组,组间差异有统计学意义(P<0.05)。两组不良反应发生率、不良事件发生率比较,组间差异无统计学意义(P>0.05)。结论 沙库巴曲缬沙坦联合螺内酯在HFrEF患者治疗中疗效显著,能够有效改善患者的心功能,提高其运动耐力,且安全可靠。Objective To investigate the clinical effect of sacubitril valsartan combined with spironolactone in the treatment of patients with heart failure with reduced ejection fraction(HFrEF).Methods A total of 80 patients with HFrEF admitted to Jinxing Hospital Affiliated to Jining Medical University from May 2022 to April 2023 were selected as the research subjects.They were divided into a control group(n=40)and an observation group(n=40)according to the random number table method.The control group was treated with spironolactone,and the observation group was treated with sacubitril valsartan on the basis of the control group,both groups were continuously treated for 2 months.The clinical efficacy,cardiac function indicators,exercise endurance,occurrence of adverse reactions,and occurrence of adverse events were compared between the two groups.Results The total effective rate of treatment in the observation group was 97.50%,which was higher than 77.50%in the control group,and the difference was statistically significant(P<0.05).After treatment,the left ventricular enddiastolic diameter and left ventricular end-systolic diameter in the observation group were shorter than those in the control group,the left ventricular ejection fraction was higher than that in the control group,and the distance of the 6-Minute Walk Test was longer than that in the control group,and the differences between the groups were statistically significant(P<0.05).A comparison of the incidence of adverse reactions and adverse events between the two groups,and there were no statistically significant difference between the groups(P>0.05).Conclusion Sacubitril valsartan combined with spironolactone has a remarkable therapeutic effect in the treatment of patients with HFrEF.It can effectively improve the cardiac function of patients,enhance their exercise endurance,and is safe and reliable.

关 键 词：射血分数降低型心力衰竭 沙库巴曲缬沙坦 螺内酯 心功能 运动耐力 

分 类 号：R541.6[医药卫生—心血管疾病]